1. Volume 14, Issue 10, Pages 1456-1463 (October 2017)
Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: Clinical characteristics and perioperative results 
Michael R. Gold, MD, PhD, FHRS, Johan D. Aasbo, DO, FHRS, Mikhael F. El-Chami, MD, FHRS, Mark Niebauer, MD, PhD, FHRS, John Herre, MD, Jordan M. Prutkin, MD, FHRS, Bradley P. Knight, MD, FHRS, Steven Kutalek, MD, FHRS, Kevin Hsu, MD, FHRS, Raul Weiss, MD, FHRS, Eric Bass, BA, Michael Husby, MS, Timothy M. Stivland, MBA, Martin C. Burke, DO 
Heart Rhythm 
Volume 14, Issue 10, Pages (October 2017)
DOI: /j.hrthm
Copyright © 2017 The Authors Terms and Conditions

2. Figure 1
PAS conversion testing. Patient flowchart for the PAS, showing the number of patients who had nonevaluable conversion tests, no testing 30 days from implantation, and at least 1 evaluable conversion test. Of those patients with evaluable conversion tests, all shock success rate and shock failure are shown along with the number of patients explanted and those patients who remained implanted. PAS = Post-Approval Study.
Heart Rhythm  , DOI: ( /j.hrthm )
Copyright © 2017 The Authors Terms and Conditions

3. Figure 2
Multivariate analysis of patient predictors of first shock failure predischarge during the index procedure. Odds ratio (OR), 95% lower and upper confidence limits (LCL, UCL), and P values are presented. BMI = body mass index; GFR = glomerular filtration rate; NYHA = New York Heart Association; TV = transvenous.
Heart Rhythm  , DOI: ( /j.hrthm )
Copyright © 2017 The Authors Terms and Conditions

4. Figure 3
Multivariate analysis of patient predictors of acute 30-day complications. Odds ratio (OR), 95% lower and upper confidence limits (LCL, UCL), and P values are presented. BL = baseline; BMI = body mass index; NYHA = New York Heart Association.
Heart Rhythm  , DOI: ( /j.hrthm )
Copyright © 2017 The Authors Terms and Conditions